Metal impurities cause false positives in high-throughput screening campaigns.

Organic impurities in compound libraries are known to often cause false-positive signals in screening campaigns for new leads, but organic impurities do not fully account for all false-positive results. We discovered inorganic impurities in our screening library that can also cause positive signals for a variety of targets and/or readout systems, including biochemical and biosensor assays. We investigated in depth the example of zinc for a specific project and in retrospect in various HTS screens at Roche and propose a straightforward counter screen using the chelator TPEN to rule out inhibition caused by zinc.

[1]  Stephen D. Roughley,et al.  The Medicinal Chemist′s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates , 2011 .

[2]  Scott R. Wilson,et al.  (Tetrakis(2-pyridylmethyl)ethylenediamine)iron(II) perchlorate, the first rapidly interconverting ferrous spin-crossover complex , 1990 .

[3]  C. Welch,et al.  High-throughput metal screening in pharmaceutical samples by ICP-MS with automated flow injection using a modified HPLC configuration. , 2010, Journal of pharmaceutical and biomedical analysis.

[4]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[5]  Paul A Johnston,et al.  Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents--real hits or promiscuous artifacts? , 2011, Current opinion in chemical biology.

[6]  Peter S. Kutchukian,et al.  Rethinking molecular similarity: comparing compounds on the basis of biological activity. , 2012, ACS chemical biology.

[7]  C. Fahrni,et al.  Aqueous Coordination Chemistry of Quinoline-Based Fluorescence Probes for the Biological Chemistry of Zinc , 1999 .

[8]  Peter Wipf,et al.  Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. , 2010, Assay and drug development technologies.

[9]  J. Broach,et al.  High-throughput screening for drug discovery. , 1996, Nature.

[10]  Peter Wipf,et al.  Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. , 2008, Assay and drug development technologies.

[11]  C. Kim,et al.  Zinc-induced NF-kappaB inhibition can be modulated by changes in the intracellular metallothionein level. , 2003, Toxicology and applied pharmacology.

[12]  M. Hsu,et al.  Structural Basis of Inhibition Specificities of 3C and 3C-like Proteases by Zinc-coordinating and Peptidomimetic Compounds , 2009, Journal of Biological Chemistry.

[13]  K. Prasad,et al.  The Art of Meeting Palladium Specifications in Active Pharmaceutical Ingredients Produced by Pd-Catalyzed Reactions , 2004 .

[14]  J. S. Carey,et al.  Analysis of the reactions used for the preparation of drug candidate molecules. , 2006, Organic & biomolecular chemistry.

[15]  G. Rishton.  Reactive compounds and in vitro false positives in HTS , 1997 .

[16]  R. Hertzberg,et al.  High-throughput screening: new technology for the 21st century. , 2000, Current opinion in chemical biology.

[17]  D. Semin,et al.  Applicability of total reflection X-ray fluorescence (TXRF) as a screening platform for pharmaceutical inorganic impurity analysis. , 2012, Journal of pharmaceutical and biomedical analysis.

[18]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[19]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[20]  J. McCusker,et al.  (Tetrakis(2-pyridylmethyl)ethylenediamine)iron(II) Perchlorate, the First Rapidly Interconverting Ferrous Spin-Crossover Complex. , 1990 .

[21]  Alexander Böcker,et al.  HTS Promiscuity Analyses for Accelerating Decision Making , 2011, Journal of biomolecular screening.

[22]  Jimmy O. DaSilva,et al.  Adsorbent Screening for Metal Impurity Removal in Pharmaceutical Process Research , 2005 .

[23]  Nicola Mongelli,et al.  NMR-based quality control approach for the identification of false positives and false negatives in high throughput screening. , 2006, Current drug discovery technologies.

[24]  P. Thompson,et al.  Protein arginine deiminase 4: a target for an epigenetic cancer therapy , 2011, Cellular and Molecular Life Sciences.

[25]  F. Siu,et al.  Metal complexes in medicine with a focus on enzyme inhibition. , 2010, Current opinion in chemical biology.

[26]  Yun He,et al.  Learning from the Data: Mining of Large High-Throughput Screening Databases , 2006, J. Chem. Inf. Model..

[27]  C. Outten,et al.  Femtomolar Sensitivity of Metalloregulatory Proteins Controlling Zinc Homeostasis , 2001, Science.

[28]  D. Giedroc,et al.  Metalloregulatory proteins: metal selectivity and allosteric switching. , 2011, Biophysical chemistry.

[29]  Robert M. Stroud,et al.  Design of potent selective zinc-mediated serine protease inhibitors , 1998, Nature.

[30]  G. Rishton.  Nonleadlikeness and leadlikeness in biochemical screening. , 2003, Drug discovery today.

[31]  S. Thrall,et al.  A Simple Assay for Detection of Small-Molecule Redox Activity , 2007, Journal of biomolecular screening.

[32]  David Mark,et al.  Biosensor-based small molecule fragment screening with biolayer interferometry , 2011, J. Comput. Aided Mol. Des..

[33]  N. Harrison,et al.  Zn2+: an endogenous modulator of ligand- and voltage-gated ion channels , 1994, Neuropharmacology.

[34]  B A Kenny,et al.  The application of high-throughput screening to novel lead discovery. , 1998, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[35]  B. Shoichet,et al.  Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.

[36]  T. Drakenberg,et al.  Spin Equilibria in Octahedral Iron(II) Complexes with Some Hexadentate Ligands of the Tetrakis(2-pyridylmethyl)ethylenediamine Type and a Spectral Correlation With Their Cobalt(III) and Nickel(II) Analogs. , 1981 .